Work

First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2501

Authors: Dejan Juric, Johann Sebastian De Bono, Patricia LoRusso, John J. Nemunaitis, Elisabeth I. Heath, Eunice Lee Kwak, Teresa Macarulla, Elena Geuna, Maria Jose de Miguel Luken, Chirag Patel, Keisuke Kuida, Serap Sankoh, Fabian Zohren, Yaping Shou, Josep Tabernero

Institutions: Massachusetts General Hospital, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Yale Cancer Center, Mary Crowley Cancer Research Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Vall d'Hebron Hospital Universitari, Candiolo Cancer Institute, Royal Marsden Hospital, Takeda Oncology (United States), Vall d'Hebron Institute of Oncology

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2278156290

Cites:

Cited by: 8

Related to: 10